Your shopping cart is currently empty

Apoptosis inducer39 is an apoptosis inducer with IC50 values of 4.53 μM for MDA-MB-231 cells and 15.42 μM for A549 cells. It exhibits antitumor activity in vitro by reducing the expression of the anti-apoptotic protein Bcl-2 and increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer39 is applicable in breast cancer and non-small cell lung cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Apoptosis inducer39 is an apoptosis inducer with IC50 values of 4.53 μM for MDA-MB-231 cells and 15.42 μM for A549 cells. It exhibits antitumor activity in vitro by reducing the expression of the anti-apoptotic protein Bcl-2 and increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer39 is applicable in breast cancer and non-small cell lung cancer research. |
| In vitro | Apoptosis inducer 39 (Compound Y22) (5-40 μM, 0-24 h) reduces the number of MDA-MB-231 cells, causing cell shrinkage and the formation of apoptotic blebs. Additionally, Apoptosis inducer 39 (5-20 μM, 24 h) significantly inhibits cell migration and exerts anti-tumor effects by inducing apoptosis in MDA-MB-231 cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.